Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas
Dohee Kwon, Sehui Kim, Pil‐Jong Kim, et al.
Histopathology (2015) Vol. 68, Iss. 7, pp. 1079-1089
Closed Access | Times Cited: 144

Showing 1-25 of 144 citing articles:

PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
Zijun Y. Xu‐Monette, Jianfeng Zhou, Ken H. Young
Blood (2017) Vol. 131, Iss. 1, pp. 68-83
Open Access | Times Cited: 368
Epstein−Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas
Eleni Anastasiadou, Dina Stroopinsky, Stella Alimperti, et al.
Leukemia (2018) Vol. 33, Iss. 1, pp. 132-147
Open Access | Times Cited: 146
Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy
Toshihiro Nagato, Takayuki Ohkuri, Kenzo Ohara, et al.
Cancer Immunology Immunotherapy (2017) Vol. 66, Iss. 7, pp. 877-890
Closed Access | Times Cited: 144
Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL
Ziju Y. Xu-Monette, Min Xiao, Qingyan Au, et al.
Cancer Immunology Research (2019) Vol. 7, Iss. 4, pp. 644-657
Open Access | Times Cited: 133
PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma
Hiroaki Miyoshi, Junichi Kiyasu, Takeharu Kato, et al.
Blood (2016) Vol. 128, Iss. 10, pp. 1374-1381
Open Access | Times Cited: 119
Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal?
Yasodha Natkunam, Dita Gratzinger, Amy Chadburn, et al.
Blood (2018) Vol. 132, Iss. 18, pp. 1871-1878
Open Access | Times Cited: 106
Advances in targeted therapy for malignant lymphoma
Li Wang, Wei Qin, Yujia Huo, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 102
Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies
Pauline Gravelle, Barbara Burroni, Sarah Péricart, et al.
Oncotarget (2017) Vol. 8, Iss. 27, pp. 44960-44975
Open Access | Times Cited: 95
Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities
Yingyue Liu, Xiangxiang Zhou, Xin Wang
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 90
Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma
Jun Zhang, L. Jeffrey Medeiros, Ken H. Young
Frontiers in Oncology (2018) Vol. 8
Open Access | Times Cited: 84
Pembrolizumab with R‐CHOP in previously untreated diffuse large B‐cell lymphoma: potential for biomarker driven therapy
Stephen D. Smith, Brian G. Till, Mazyar Shadman, et al.
British Journal of Haematology (2020) Vol. 189, Iss. 6, pp. 1119-1126
Open Access | Times Cited: 83
The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma
Benjamin J. Chen, Dashnamoorthy Ravi, Pallavi Galera, et al.
Oncotarget (2019) Vol. 10, Iss. 21, pp. 2030-2040
Open Access | Times Cited: 76
PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas
Wei Xie, L. Jeffrey Medeiros, Shaoying Li, et al.
Current Hematologic Malignancy Reports (2020) Vol. 15, Iss. 4, pp. 372-381
Closed Access | Times Cited: 70
Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems
Stefano Marletta, Nicola Fusco, Enrico Munari, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 7, pp. 1073-1073
Open Access | Times Cited: 64
PD-L1+ tumor-associated macrophages and PD-1+ tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma
Marjukka Pollari, Oscar Brück, Teijo Pellinen, et al.
Haematologica (2018) Vol. 103, Iss. 11, pp. 1908-1914
Open Access | Times Cited: 71
PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas
Marién Pascual, Maria Mena‐Varas, Eloy F. Robles, et al.
Blood (2019) Vol. 133, Iss. 22, pp. 2401-2412
Open Access | Times Cited: 71
PD-L1 and tumor-associated macrophages in de novo DLBCL
Ronald McCord, Christopher R. Bolen, Hartmut Koeppen, et al.
Blood Advances (2019) Vol. 3, Iss. 4, pp. 531-540
Open Access | Times Cited: 68
PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT)
Rong He, Wei Ding, David S. Viswanatha, et al.
The American Journal of Surgical Pathology (2018) Vol. 42, Iss. 7, pp. 843-854
Closed Access | Times Cited: 63
Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma
Gyung Hyuck Ko, Byeong-Bae Park, Jieun Uhm
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 6, pp. 1326-1326
Open Access | Times Cited: 63
PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications
Xing Wei, Karen Dresser, Rui Zhang, et al.
Oncotarget (2016) Vol. 7, Iss. 37, pp. 59976-59986
Open Access | Times Cited: 62
Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma
Mixue Xie, Xianbo Huang, Xiujin Ye, et al.
International Immunopharmacology (2019) Vol. 77, pp. 105999-105999
Closed Access | Times Cited: 55
Immune-Checkpoint Inhibitors in B-Cell Lymphoma
Marc Armengol, Juliana C. Santos, Miranda Fernández-Serrano, et al.
Cancers (2021) Vol. 13, Iss. 2, pp. 214-214
Open Access | Times Cited: 42
Programmed death‐ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2‐negative status
Lei Wang, Qiongyan Zhang, Shujuan Ni, et al.
Cancer Medicine (2018) Vol. 7, Iss. 6, pp. 2612-2620
Open Access | Times Cited: 57
The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma
Fang Xia, Bing Xiu, Zhi-Zhang Yang, et al.
Medicine (2017) Vol. 96, Iss. 15, pp. e6398-e6398
Open Access | Times Cited: 55
Immunohistochemical assessment of the diagnostic utility of PD‐L1: a preliminary analysis of anti‐PD‐L1 antibody (SP142) for lymphoproliferative diseases with tumour and non‐malignant Hodgkin–Reed‐Sternberg (HRS)‐like cells
Ayako Sakakibara, Kei Kohno, Ahmed E. Eladl, et al.
Histopathology (2018) Vol. 72, Iss. 7, pp. 1156-1163
Closed Access | Times Cited: 49
Page 1 - Next Page

Scroll to top